Video
Dr. Chamie on durability of UGN-101 in low-grade UTUC
Author(s):
“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.
Video Player is loading.
In this video, Karim Chamie, MD, discusses the background of the study, “Long-term recurrence free survival following UGN-101 treatment for low-grade upper tract urothelial carcinoma,” presented at the 2021 American Urological Association Annual Meeting, and how it builds on previous studies. Chamie is an associate professor of urology and director of the Urologic Oncology Fellowship at the University of California, Los Angeles.
Related Videos
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
Related Content
